NASDAQ:MAZE
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. reported net income of −$131.1M in fiscal 2025. Free cash flow was −$112.7M, and the diluted share count rose 1474.0%.Summary generated from Maze Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−599.0%
Debt / equityn/a
Free cash flow−$112.7M
FCF marginn/a
Share count change+1474.0%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 168 | n/a |
| Operating income | 58 | −143 |
| Net income | 52 | −131 |
| Free cash flow | 75 | −113 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KDirector or officer change
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 8-KDirector or officer change
May 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026